Form 4: AN2 Therapeutics Executive Sells Shares to Cover Tax Obligations

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, sold 2,029 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Stephen David Prior, the Chief Strategy Officer of AN2 Therapeutics, sold 2,029 shares of common stock on January 3, 2025.
• The sale was executed at a price of $1.341 per share.
• This transaction was to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2025.
• Following the transaction, Prior beneficially owns 33,313 shares of common stock.
• This includes 10,125 RSUs vesting over four years from November 4, 2024, and 12,031 RSUs vesting on January 1, 2026, subject to continued service with the company.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the industry.
• The number of shares sold and the price are specific to the individual's compensation package and the company's stock performance.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale by an executive to cover tax obligations.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Stephen David Prior, Chief Strategy Officer, stock sale, Form 4, Restricted Stock Units, RSUs, tax obligations, insider trading